MC

462.1

-0.18%↓

BNP

78.49

+3.14%↑

DB1.DE

256.7

+0.9%↑

NDA.FI

12.8

+1.51%↑

BKT

12.51

+1.54%↑

MC

462.1

-0.18%↓

BNP

78.49

+3.14%↑

DB1.DE

256.7

+0.9%↑

NDA.FI

12.8

+1.51%↑

BKT

12.51

+1.54%↑

MC

462.1

-0.18%↓

BNP

78.49

+3.14%↑

DB1.DE

256.7

+0.9%↑

NDA.FI

12.8

+1.51%↑

BKT

12.51

+1.54%↑

MC

462.1

-0.18%↓

BNP

78.49

+3.14%↑

DB1.DE

256.7

+0.9%↑

NDA.FI

12.8

+1.51%↑

BKT

12.51

+1.54%↑

MC

462.1

-0.18%↓

BNP

78.49

+3.14%↑

DB1.DE

256.7

+0.9%↑

NDA.FI

12.8

+1.51%↑

BKT

12.51

+1.54%↑

Search

Sartorius Stedim Biotech.

Open

SectorFinance

170.8 -0.41

Overview

Share price change

24h

Current

Min

169.2

Max

172.15

Key metrics

By Trading Economics

Income

-47M

69M

Sales

400K

745M

P/E

Sector Avg

76.147

25.916

EPS

1.18

Dividend yield

0.39

Profit margin

9.195

Employees

10,030

EBITDA

124M

256M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+33.63% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

0.39%

3.70%

Next Earnings

16 Oct 2025

Market Stats

By TradingEconomics

Market Cap

92M

20B

Previous open

171.21

Previous close

170.8

News Sentiment

By Acuity

20%

80%

29 / 536 Finance

Technical Score

By Trading Central

Confidence

Bullish Evidence

Sartorius Stedim Biotech. Chart

Past performance is not a reliable indicator of future results.

Related News

4 Aug 2025, 21:42 UTC

Earnings
Acquisitions, Mergers, Takeovers

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

4 Aug 2025, 21:21 UTC

Earnings
Major Market Movers

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4 Aug 2025, 20:45 UTC

Earnings

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4 Aug 2025, 19:15 UTC

Major Market Movers

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

4 Aug 2025, 23:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 Aug 2025, 23:41 UTC

Market Talk

Nikkei May Rise on Fed Stimulus Hopes

4 Aug 2025, 23:28 UTC

Market Talk

Global Equities Roundup: Market Talk

4 Aug 2025, 23:28 UTC

Market Talk

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

4 Aug 2025, 21:30 UTC

Earnings

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 Aug 2025, 21:21 UTC

Earnings
Acquisitions, Mergers, Takeovers

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

4 Aug 2025, 21:18 UTC

Earnings

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 Aug 2025, 20:25 UTC

Market Talk

India Hits Back Over Russian Oil Purchases -- Market Talk

4 Aug 2025, 20:25 UTC

Earnings

Transocean 2Q Loss $938M >RIG

4 Aug 2025, 20:25 UTC

Earnings

Transocean 2Q Loss/Shr $1.06 >RIG

4 Aug 2025, 20:18 UTC

Earnings

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

4 Aug 2025, 20:15 UTC

Earnings

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

4 Aug 2025, 20:14 UTC

Earnings

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

4 Aug 2025, 20:14 UTC

Earnings

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

4 Aug 2025, 20:14 UTC

Earnings

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

4 Aug 2025, 20:13 UTC

Earnings

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

4 Aug 2025, 20:09 UTC

Earnings

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

4 Aug 2025, 20:06 UTC

Earnings

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

4 Aug 2025, 20:01 UTC

Earnings

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

4 Aug 2025, 20:01 UTC

Earnings

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

4 Aug 2025, 20:01 UTC

Earnings

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

4 Aug 2025, 20:01 UTC

Earnings

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

4 Aug 2025, 19:41 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower -- Market Talk

4 Aug 2025, 19:28 UTC

Market Talk

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

4 Aug 2025, 19:07 UTC

Market Talk

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

4 Aug 2025, 18:27 UTC

Market Talk

Gold Climbs on Rate Cut Speculation -- Market Talk

Peer Comparison

Price change

Sartorius Stedim Biotech. Forecast

Price Target

By TipRanks

33.63% upside

12 Months Forecast

Average 229.38 EUR  33.63%

High 245 EUR

Low 210 EUR

Based on 8 Wall Street analysts offering 12 month price targets forSartorius Stedim Biotech. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

6

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

202.7 / 211.7Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Strong Bullish Evidence

Sentiment

By Acuity

29 / 536 Finance

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.